KRAS-Mutated Metastatic CRC
KRAS-Mutated Metastatic CRC
Case: A 38-year Old Woman WithKRAS-Mutated mCRC
Initial presentation
- A 38-year old woman was referred to gastroenterology after experiencing several bouts of bloody diarrhea
- PMH: unremarkable
- PE: unremarkable
Clinical workup
- Colonoscopy: suspicious sigmoid mass, partial obstruction
- Biopsy: poorly differentiated adenocarcinoma
- Imaging: CT scan of the chest/abdomen/pelvis revealed multiple small bilateral liver metastases
- Molecular testing on tissue biopsy:
- Positive forKRASexon 2 codon 12 mutation
- Negative forNRAS,BRAF
- Microsatellite-stable
- Diagnosis: stage IV colorectal cancer
- ECOG PS 0
Treatment
- She underwent laparoscopic sigmoid resection
- She was initiated on treatment with FOLFOX + bevacizumab; well-tolerated
- Follow-up imaging at 3 and 6 months showed a partial response
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
